CPA
HTGM

Cowen Prime Advisors’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Cowen Prime Advisors’s Portfolio HTGM Stock Details HTGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-27,683
Closed -$462K – 183
2022
Q1 		$462K Sell
27,683
-21,745
-44% -$698K 0.19% 59
2021
Q4 		$3.21M Sell
49,428
-8,783
-15% -$511K 1.09% 23
2021
Q3 		$3.99M Buy
58,211
+10,683
+22% +$764K 1.48% 15
2021
Q2 		$3.31M Buy
47,528
+3,859
+9% +$209K 1.2% 20
2021
Q1 		$2.87M Buy
43,669
+6,842
+19% +$519K 1.08% 23
2020
Q4 		$2.12M Buy
36,827
+28,985
+370% +$1.69M 0.94% 24
2020
Q3 		$466K Buy
+7,842
New +$700K 0.23% 54
2020
Q2 		– Sell
-24,753
Closed -$1.45M – 218
2020
Q1 		$1.45M Buy
24,753
+12,876
+108% +$1.26M 0.88% 28
2019
Q4 		$1.5M Buy
11,877
+11,321
+2,036% +$1.53M 0.69% 35
2019
Q3 		$66K Buy
556
+500
+893% +$101K 0.03% 104
2019
Q2 		$17K Sell
56
-55
-50% -$22.9K 0.01% 143
2019
Q1 		$50K Buy
+111
New +$48.6K 0.03% 116

Other funds holding HTGM

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Cowen Prime Advisors's HTGM Position: Q2 2022 in Review

Cowen Prime Advisors sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q2 2022, closing a stake of 27,683 shares — an estimated $462K sold.

Cowen Prime Advisors first reported a position in HTGM in Q1 2019 and held it in 12 quarters. The position peaked at $3.99M in Q3 2021. 21 funds tracked by Wall St. Rank hold HTGM as of Q2 2022.

  • Cowen Prime Advisors reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Cowen Prime Advisors sold 27,683 HTG Molecular Diagnostics, Inc. Common Stock shares in Q2 2022, an estimated $462K.
  • Cowen Prime Advisors first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q1 2019 and held it in 12 quarters.
  • Cowen Prime Advisors's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $3.99M in Q3 2021.
  • 21 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q2 2022.

Based on Cowen Prime Advisors's 13F filing for Q2 2022, filed 1 Aug 2022.